NCT02804568View on ClinicalTrials.gov

A Phase 1 Safety Study in Adults With Schizophrenia

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions
Schizophrenia
Interventions
DRUG

ALKS 3831

Oral capsule, daily administration

Trial Locations (3)

45417

Alkermes Investigational Site, Dayton

72205

Alkermes Investigational Site, Little Rock

08021

Alkermes Investigational Site, Clementon

Sponsors

Lead Sponsor

Alkermes, Inc.
All Listed Sponsors
lead

Alkermes, Inc.

INDUSTRY